Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy
- Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy
NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that a presentation of data from the pivotal Phase 3 SIERRA trial of Iomab-B has been selected as one of four late breaking oral presentations at the 2019 TCT or Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR, which is being held February 20 – 24 in Houston, Texas. In addition, three abstracts related to Actinium’s targeted conditioning pipeline have been accepted for poster presentations.
Sandesh Seth, Chairman and CEO of Actinium, said, “TCT is the ideal venue for us to present data and highlight our targeted conditioning programs as it is the pre-eminent medical meeting focused on bone marrow transplant and cellular therapy. We are excited to have multiple opportunities to highlight clinical data for Iomab-as well as update on Iomab-ACT, our newest program focused on lymphodepletion prior to CAR-T. In addition, we are involved with several events, educational and otherwise, that will enable us to educate a broad audience of investigators, researchers and potential partners about the SIERRA trial and our highly differentiated multi-disease, multi-target targeted conditioning pipeline. We expect this meeting to be a highly productive and consequential one for our company.”
Highlights of Actinium’s key meeting activities are:
Late Breaking Oral Presentation
| Title: | Novel Re-Induction and Anti-CD45 Targeted Conditioning with Iodine (131I) Apamistamab [Iomab-B] Yields Encouraging Results in Older Patients with Active, Relapsed or Refractory AML: Safety & Feasibility Data from the Prospective Randomized Phase III SIERRA Trial |
| Presenter: | Sergio Giralt, MD, Chief Attending Physician, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center |
| Time: | Sunday, February 24th, 12:30-12:45 PM CT |
| Location: | Hilton Americas - Grand Ballroom A |
Poster Presentations
| Poster Title: | Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy or CAR-T |
| Presenter: | Dale Ludwig, PhD, Chief Scientific Officer, Actinium Pharmaceuticals, Inc. |
| Time: | Wednesday, February 20th, 6:45 – 7:45 PM CT |
| Location: | George R. Brown Convention Center – GRB Exhibit Hall B3 |
| Poster Title: | Survival of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients Receiving Stem Cell Transplantation (SCT) |
| Presenter: | Rajneesh Nath, MD, Director Bone Marrow Transplant & Acute Leukemia Program, Banner MD Anderson Cancer Center |
| Time: | Wednesday, February 20th, 6:45 – 7:45 PM CT |
| Location: | George R. Brown Convention Center – GRB Exhibit Hall B3 |
| Poster Title: | Burden of Hospitalization in Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia |
| Presenter: | Vijay Reddy, MD, PhD, Vice President, Clinical Development and Head of Bone Marrow Transplant, Actinium Pharmaceuticals, Inc. |
| Time: | Wednesday, February 20th, 6:45 – 7:45 PM CT |
| Location: | George R. Brown Convention Center – GRB Exhibit Hall B3 |
TCT 2019 Satellite Symposium
Satellite symposia are attended by nearly 2,000 physicians, scientists and allied health professionals working in blood and marrow transplantation in BMT programs throughout the United States, Canada and over 30 other countries.
| Title: | Integrating Innovative Therapeutics with Allogeneic HSCT in AML: Insights and Evidence from Induction to Maintenance |
| Presenters: | James Foran, MD, Associate Professor of Medicine, Mayo Clinic and Alexander Perl, MD, Associate Professor of Medicine, University of Pennsylvania |
| Time: | Saturday, February 23rd, 12:30 – 1:30 PM |
| Location: | George R. Brown Convention Center, Grand Ballroom ABC |
Dr. Mark Berger, Chief Medical Officer of Actinium commented, “TCT brings together the close-knit community of BMT and CAR-T physicians and health professionals resulting in an incredibly productive and valuable meeting. We are honored to have the opportunity to share so much of our research and clinical programs with the meeting attendees this year. Given the recent promising data presented at ASH for Iomab-B, our late breaking oral presentation for Iomab-B and the recent launch of our Iomab-ACT program for CAR-T, I expect this year to be our most productive and rewarding conference yet.”
About Transplantation & Cellular Therapy Meetings™ (TCT)
TCT, formerly known as the BMT Tandem Meetings, are the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Each year the conference brings together several thousand investigators, clinicians, researchers, nurses and other allied health professionals from over 500 transplant centers from over 50 countries around a full scientific program focused on bone marrow transplant and cellular therapies.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free or sparing, targeted conditioning technology. Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by ARC’s or Antibody Radiation Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium’s pipeline of clinical-stage targeted conditioning ARCs target the antigens CD45 and CD33 for patients with a broad range of hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), acute lymphoblastic leukemia (ALL), Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma. Actinium’s Iomab-ACT program is designed to be a universal lymphodepletion technology intended to eliminate the need for chemotherapy-based conditioning prior to CAR-T or other adoptive cellular therapies.
Iomab-B, Actinium’s lead targeted conditioning product candidate, is currently enrolling patients in the pivotal Phase 3 SIERRA trial in patients age 55 or older, with active, relapsed or refractory AML. Iodine-131-apamistamab (Iomab-B), combines the anti-CD45 monoclonal antibody labeled with iodine-131 for myeloablation prior to a bone marrow transplant. CD45 is expressed on leukemia, lymphoma and normal immune cells. Iomab-B has been studied in over 500 patients in 10 clinical trials in numerous hematologic diseases. Actinium’s Iomab-ACT program is an expansion of its CD45 program that is intended to be a universal, chemotherapy-free solution for targeted lymphodepletion prior to CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is expected to improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment and potentially other adoptive cell therapies. Due to its lower payload dose, lymphodepletion with the Iomab-ACT program can be accomplished through a single outpatient infusion. Actinium intends to advance its Iomab-ACT program with CAR-T focused collaborators from academia and industry.
Actinium’s pipeline also includes a potentially best-in-class CD33 program with its ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in multiple clinical trials for targeting conditioning and as a therapeutic in multiple diseases and indications including AML, MDS and MM. Actinium applies its CD33 program at high doses to target CD33+ cells of the myeloid lineage in combination with reduced intensity conditioning (RIC), which together are intended to result in myeloablative outcomes with a more benign and well tolerated profile than high intensity chemotherapy myeloablation. Actinium is focused on applying its CD33 program at low doses in combination with other therapeutic modalities including chemotherapy, targeted agents and immunotherapies.
Actinium is also developing its proprietary AWE or Antibody Warhead Enabling technology platform which utilizes radioisotopes including iodine-131 and the highly differentiated actinium-225 coupled with antibodies to target a variety of antigens that are expressed in hematological and solid tumor cancers. The AWE technology enables Actinium’s internal pipeline and with the radioisotope Actinium-225 is being utilized in a collaborative research partnership with Astellas Pharma, Inc. Actinium’s clinical programs and AWE technology platform are covered by a portfolio of 75 patents covering composition of matter, formulations, methods of use and also methods of manufacturing the radioisotope Actinium-225 in a cyclotron.
More information is available at www.actiniumpharma.com and our Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Investor Contacts:
Actinium Pharmaceuticals, Inc.
Steve O’Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 535-7743
View original content:http://www.prnewswire.com/news-releases/iomab-b-one-of-four-late-breaking-oral-presentations-to-be-presented-at-the-2019-transplantation--cellular-therapy-annual-meeting-300793634.html
SOURCE Actinium Pharmaceuticals, Inc.
Company Codes: AMEX:ATNM
